Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	New Amedeo service: Amedeo COVID-19 (formerly 2019-nCoV) Weekly publication summary

Lung Cancer

Free Subscription Articles published in Lancet Oncol Retrieve available abstracts of 93 articles: HTML format Text format

Single Articles

February 2020
1. GARASSINO MC, Gadgeel S, Esteban E, Felip E, et al
   Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-contro
   Lancet Oncol. 2020 Feb 6. pii: S1470-2045(19)30801.
   PubMed     Text format     Abstract available
   
   
   
2. FUNG AS, Leighl NB
   Advancing the systemic therapy of lung cancer: quality or quantity?
   Lancet Oncol. 2020 Feb 6. pii: S1470-2045(20)30076.
   PubMed     Text format    
   
   
   
3. SEQUIST LV, Han JY, Ahn MJ, Cho BC, et al
   Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
   Lancet Oncol. 2020 Feb 3. pii: S1470-2045(19)30785.
   PubMed     Text format     Abstract available
   
   
   
4. SCHMID S, Fruh M, Peters S
   Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
   Lancet Oncol. 2020 Feb 3. pii: S1470-2045(19)30859.
   PubMed     Text format    
   
   
   December 2019
5. DRILON A, Siena S, Dziadziuszko R, Barlesi F, et al
   Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
   Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30690.
   PubMed     Text format     Abstract available
   
   
   October 2019
6. DURUISSEAUX M
   Lorlatinib: a new treatment option for ROS1-positive lung cancer.
   Lancet Oncol. 2019 Oct 25. pii: S1470-2045(19)30716.
   PubMed     Text format    
   
   
   
7. SHAW AT, Solomon BJ, Chiari R, Riely GJ, et al
   Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
   Lancet Oncol. 2019 Oct 25. pii: S1470-2045(19)30655.
   PubMed     Text format     Abstract available
   
   
   
8. HUI R, Ozguroglu M, Villegas A, Daniel D, et al
   Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
   Lancet Oncol. 2019 Oct 7. pii: S1470-2045(19)30519.
   PubMed     Text format     Abstract available
   
   
   
9. ANOTA A, Westeel V
   Quality of life with durvalumab in stage III non-small-cell lung cancer.
   Lancet Oncol. 2019 Oct 7. pii: S1470-2045(19)30643.
   PubMed     Text format    
   
   
   
10. NAKAGAWA K, Garon EB, Seto T, Nishio M, et al
    Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Oct 4. pii: S1470-2045(19)30634.
    PubMed     Text format     Abstract available
    
    
    
11. ROSELL R, Pedraz-Valdunciel C
    Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?
    Lancet Oncol. 2019 Oct 4. pii: S1470-2045(19)30636.
    PubMed     Text format    
    
    
    
12. AHN MJ, Han JY, Lee KH, Kim SW, et al
    Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
    Lancet Oncol. 2019 Oct 3. pii: S1470-2045(19)30504.
    PubMed     Text format     Abstract available
    
    
    
13. FIERO MH, Roydhouse JK, Vallejo J, King-Kallimanis BL, et al
    US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017.
    Lancet Oncol. 2019;20:e582-e589.
    PubMed     Text format     Abstract available
    
    
    September 2019
14. CAPPUZZO F, West H
    Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2019;20:e467.
    PubMed     Text format    
    
    
    
15. UPRETY D
    Chemoimmunotherapy for stage IV non-small-cell lung cancer.
    Lancet Oncol. 2019;20:e466.
    PubMed     Text format    
    
    
    August 2019
16. ANTONIA SJ, Borghaei H, Ramalingam SS, Horn L, et al
    Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
    Lancet Oncol. 2019 Aug 14. pii: S1470-2045(19)30407.
    PubMed     Text format     Abstract available
    
    
    
17. SOUQUET PJ, Couraud S
    Immune checkpoint inhibitors: a game changer for metastatic non-small-cell lung cancer.
    Lancet Oncol. 2019 Aug 14. pii: S1470-2045(19)30508.
    PubMed     Text format    
    
    
    July 2019
18. HERBST RS, Arkenau HT, Santana-Davila R, Calvo E, et al
    Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Lancet Oncol. 2019 Jul 10. pii: S1470-2045(19)30458.
    PubMed     Text format     Abstract available
    
    
    June 2019
19. LUO YH, Luo L, Wampfler JA, Wang Y, et al
    5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study.
    Lancet Oncol. 2019 Jun 26. pii: S1470-2045(19)30329.
    PubMed     Text format     Abstract available
    
    
    
20. BERG CD
    Improving selection of individuals into lung cancer screening programmes.
    Lancet Oncol. 2019 Jun 26. pii: S1470-2045(19)30411.
    PubMed     Text format    
    
    
    May 2019
21. LI Y, Wu YL
    The second wave of checkpoint inhibitors with chemotherapy for advanced non-small-cell lung cancer.
    Lancet Oncol. 2019 May 20. pii: S1470-2045(19)30148.
    PubMed     Text format    
    
    
    
22. WEST H, McCleod M, Hussein M, Morabito A, et al
    Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3
    Lancet Oncol. 2019 May 20. pii: S1470-2045(19)30167.
    PubMed     Text format     Abstract available
    
    
    April 2019
23. SAITO H, Fukuhara T, Furuya N, Watanabe K, et al
    Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
    Lancet Oncol. 2019 Apr 8. pii: S1470-2045(19)30035.
    PubMed     Text format     Abstract available
    
    
    February 2019
24. ALSHAFA F, Palma D
    CHISELing a path forward in the treatment of early-stage non-small-cell lung cancer.
    Lancet Oncol. 2019 Feb 12. pii: S1470-2045(18)30953.
    PubMed     Text format    
    
    
    
25. BALL D, Mai GT, Vinod S, Babington S, et al
    Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Lancet Oncol. 2019 Feb 12. pii: S1470-2045(18)30896.
    PubMed     Text format     Abstract available
    
    
    November 2018
26. SOLOMON BJ, Besse B, Bauer TM, Felip E, et al
    Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Lancet Oncol. 2018 Nov 6. pii: S1470-2045(18)30649.
    PubMed     Text format     Abstract available
    
    
    September 2018
27. ROSELL R, Karachaliou N
    Avelumab in non-small-cell lung cancer.
    Lancet Oncol. 2018 Sep 21. pii: S1470-2045(18)30683.
    PubMed     Text format    
    
    
    
28. BARLESI F, Vansteenkiste J, Spigel D, Ishii H, et al
    Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
    Lancet Oncol. 2018 Sep 21. pii: S1470-2045(18)30673.
    PubMed     Text format     Abstract available
    
    
    
29. BLACKHALL F, Frese KK, Simpson K, Kilgour E, et al
    Will liquid biopsies improve outcomes for patients with small-cell lung cancer?
    Lancet Oncol. 2018;19:e470-e481.
    PubMed     Text format     Abstract available
    
    
    August 2018
30. HIOM SC, Kumar HS, Swanton C, Baldwin DR, et al
    Lung cancer in the UK: addressing geographical inequality and late diagnosis.
    Lancet Oncol. 2018;19:1015-1017.
    PubMed     Text format    
    
    
    July 2018
31. GLANVILLE AR, Wilson BE
    Lung transplantation for non-small cell lung cancer and multifocal bronchioalveolar cell carcinoma.
    Lancet Oncol. 2018;19:e351-e358.
    PubMed     Text format     Abstract available
    
    
    
32. BAAS P, Burgers S
    Malignant pleural effusions: will PROMISE make its name true?
    Lancet Oncol. 2018;19:853-855.
    PubMed     Text format    
    
    
    
33. LUCAS C
    Miracle mineral or mesothelioma: cancer and asbestos in the USA.
    Lancet Oncol. 2018;19:868.
    PubMed     Text format    
    
    
    June 2018
34. GOURD E
    Lung cancer incidence higher in US women than men.
    Lancet Oncol. 2018 Jun 1. pii: S1470-2045(18)30422.
    PubMed     Text format    
    
    
    
35. GREGORC V, Gaafar RM, Favaretto A, Grossi F, et al
    NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet Oncol. 2018;19:799-811.
    PubMed     Text format     Abstract available
    
    
    April 2018
36. ROLFO C, Smits ELJ
    Combining top-ranked immunotherapeutics in lung cancer.
    Lancet Oncol. 2018 Apr 5. pii: S1470-2045(18)30186.
    PubMed     Text format    
    
    
    
37. WRANGLE JM, Velcheti V, Patel MR, Garrett-Mayer E, et al
    ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
    Lancet Oncol. 2018 Apr 5. pii: S1470-2045(18)30148.
    PubMed     Text format     Abstract available
    
    
    March 2018
38. LIN JJ, Gainor JF
    ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?
    Lancet Oncol. 2018 Mar 12. pii: S1470-2045(18)30160.
    PubMed     Text format    
    
    
    
39. GARASSINO MC, Cho BC, Kim JH, Mazieres J, et al
    Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Lancet Oncol. 2018 Mar 12. pii: S1470-2045(18)30144.
    PubMed     Text format     Abstract available
    
    
    
40. FIELD JK, Heuvelmans MA, Devaraj A, Heussel CP, et al
    Low-dose CT for lung cancer screening - Authors' reply.
    Lancet Oncol. 2018;19:e135-e136.
    PubMed     Text format    
    
    
    
41. BACH PB, Brawley OW, Silvestri GA
    Low-dose CT for lung cancer screening.
    Lancet Oncol. 2018;19:e133-e134.
    PubMed     Text format    
    
    
    
42. RUANO-RAVINA A, Perez-Rios M, Casan-Clara P, Provencio-Pulla M, et al
    Low-dose CT for lung cancer screening.
    Lancet Oncol. 2018;19:e131-e132.
    PubMed     Text format    
    
    
    
43. WU YL, Zhong WZ
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2018;19:e127.
    PubMed     Text format    
    
    
    
44. ROSELL R, Karachaliou N
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e126.
    PubMed     Text format    
    
    
    
45. MA JA, Jiang S, Hu C, Xie Y, et al
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e125.
    PubMed     Text format    
    
    
    
46. WU F, Liu X, Ma JA, Gao Y, et al
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e124.
    PubMed     Text format    
    
    
    
47. SCHERPEREEL A, Wallyn F, Albelda SM, Munck C, et al
    Novel therapies for malignant pleural mesothelioma.
    Lancet Oncol. 2018;19:e161-e172.
    PubMed     Text format     Abstract available
    
    
    February 2018
48. ILEANA-DUMBRAVA E, Subbiah V
    Autoimmune hypophysitis.
    Lancet Oncol. 2018;19:e123.
    PubMed     Text format    
    
    
    January 2018
49. CHENG H, Perez-Soler R
    Leptomeningeal metastases in non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e43-e55.
    PubMed     Text format     Abstract available
    
    
    
50. WU YL, Mok TS
    Dacomitinib in NSCLC: a positive trial with little clinical impact - Authors' reply.
    Lancet Oncol. 2018;19:e5.
    PubMed     Text format    
    
    
    
51. ADDEO A
    Dacomitinib in NSCLC: a positive trial with little clinical impact.
    Lancet Oncol. 2018;19:e4.
    PubMed     Text format    
    
    
    
52. NG TL, Camidge DR
    Lung cancer's real adjuvant EGFR targeted therapy questions.
    Lancet Oncol. 2018;19:15-17.
    PubMed     Text format    
    
    
    
53. PIRKER R
    EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation.
    Lancet Oncol. 2018;19:10-12.
    PubMed     Text format    
    
    
    
54. STIRRUPS R
    Osimertinib improves progression-free survival in NSCLC.
    Lancet Oncol. 2018;19:e10.
    PubMed     Text format    
    
    
    
55. GOURD E
    Durvalumab boosts progression-free survival in NSCLC.
    Lancet Oncol. 2018;19:e11.
    PubMed     Text format    
    
    
    
56. ZHONG WZ, Wang Q, Mao WM, Xu ST, et al
    Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Lancet Oncol. 2018;19:139-148.
    PubMed     Text format     Abstract available
    
    
    
57. HERBST RS, Redman MW, Kim ES, Semrad TJ, et al
    Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Lancet Oncol. 2018;19:101-114.
    PubMed     Text format     Abstract available
    
    
    December 2017
58. OUDKERK M, Devaraj A, Vliegenthart R, Henzler T, et al
    European position statement on lung cancer screening.
    Lancet Oncol. 2017;18:e754-e766.
    PubMed     Text format     Abstract available
    
    
    
59. EMERY JD, Mitchell PL
    Lung cancer in Asian women and health system implications for Australia.
    Lancet Oncol. 2017;18:1570-1571.
    PubMed     Text format    
    
    
    
60. BRAHMER JR, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
    Lancet Oncol. 2017;18:1600-1609.
    PubMed     Text format     Abstract available
    
    
    
61. FEROLLA P, Brizzi MP, Meyer T, Mansoor W, et al
    Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
    Lancet Oncol. 2017;18:1652-1664.
    PubMed     Text format     Abstract available
    
    
    November 2017
62. WEISS J
    Bevacizumab in adjuvant treatment of non-small-cell lung cancer.
    Lancet Oncol. 2017 Nov 9. pii: S1470-2045(17)30843.
    PubMed     Text format    
    
    
    
63. WAKELEE HA, Dahlberg SE, Keller SM, Tester WJ, et al
    Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
    Lancet Oncol. 2017 Nov 9. pii: S1470-2045(17)30691.
    PubMed     Text format     Abstract available
    
    
    October 2017
64. SHAW AT, Felip E, Bauer TM, Besse B, et al
    Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Lancet Oncol. 2017 Oct 23. pii: S1470-2045(17)30680.
    PubMed     Text format     Abstract available
    
    
    
65. DE KONING HJ
    Lung cancer screening and its continuous risk assessment.
    Lancet Oncol. 2017 Oct 16. pii: S1470-2045(17)30730.
    PubMed     Text format    
    
    
    
66. TAMMEMAGI MC, Schmidt H, Martel S, McWilliams A, et al
    Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
    Lancet Oncol. 2017 Oct 16. pii: S1470-2045(17)30597.
    PubMed     Text format     Abstract available
    
    
    
67. FAIVRE-FINN C, Ryder WD, Blackhall F
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer? - Authors' reply.
    Lancet Oncol. 2017;18:e556.
    PubMed     Text format    
    
    
    
68. EZE C, Roengvoraphoj O, Dantes M, Manapov F, et al
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e555.
    PubMed     Text format    
    
    
    
69. MITIN T, Farrell M, Holland J, Cetnar J, et al
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e554.
    PubMed     Text format    
    
    
    
70. ZENG H, Yu J, Yuan S
    Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
    Lancet Oncol. 2017;18:e553.
    PubMed     Text format    
    
    
    
71. VAN ZANDWIJK N, Pavlakis N, Kao SC, Linton A, et al
    Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    Lancet Oncol. 2017;18:1386-1396.
    PubMed     Text format     Abstract available
    
    
    
72. PAVEL ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, et al
    Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase
    Lancet Oncol. 2017;18:1411-1422.
    PubMed     Text format     Abstract available
    
    
    September 2017
73. BRUECKL WM
    Treatment choice in EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2017 Sep 25. pii: S1470-2045(17)30684.
    PubMed     Text format    
    
    
    
74. WU YL, Cheng Y, Zhou X, Lee KH, et al
    Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2017 Sep 25. pii: S1470-2045(17)30608.
    PubMed     Text format     Abstract available
    
    
    
75. PLANCHARD D, Smit EF, Groen HJM, Mazieres J, et al
    Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
    Lancet Oncol. 2017 Sep 8. pii: S1470-2045(17)30679.
    PubMed     Text format     Abstract available
    
    
    
76. PERROT M, Wu L, Wu M, Cho BCJ, et al
    Radiotherapy for the treatment of malignant pleural mesothelioma.
    Lancet Oncol. 2017;18:e532-e542.
    PubMed     Text format     Abstract available
    
    
    
77. MAIO M, Scherpereel A, Calabro L, Aerts J, et al
    Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
    Lancet Oncol. 2017;18:1261-1273.
    PubMed     Text format     Abstract available
    
    
    July 2017
78. AKAMATSU H, Takahashi T, Yamamoto N
    Prophylactic cranial irradiation in small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2017;18:e369.
    PubMed     Text format    
    
    
    
79. FAN X, Liang F, Zhu J
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e368.
    PubMed     Text format    
    
    
    
80. WEISS GJ, Lohinai Z
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e367.
    PubMed     Text format    
    
    
    
81. MANAPOV F, Eze C
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e366.
    PubMed     Text format    
    
    
    
82. RUSTHOVEN CG, Kavanagh BD
    Prophylactic cranial irradiation in small-cell lung cancer.
    Lancet Oncol. 2017;18:e365.
    PubMed     Text format    
    
    
    
83. DEL PAGGIO JC, Sullivan R, Schrag D, Hopman WM, et al
    Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
    Lancet Oncol. 2017;18:887-894.
    PubMed     Text format     Abstract available
    
    
    June 2017
84. BROWER V
    Atezolizumab in advanced non-small-cell lung cancer.
    Lancet Oncol. 2017 Jun 22. pii: S1470-2045(17)30504.
    PubMed     Text format    
    
    
    
85. FAIVRE-FINN C, Snee M, Ashcroft L, Appel W, et al
    Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
    Lancet Oncol. 2017 Jun 19. pii: S1470-2045(17)30318.
    PubMed     Text format     Abstract available
    
    
    
86. FIETKAU R
    Which fractionation of radiotherapy is best for limited-stage small-cell lung cancer?
    Lancet Oncol. 2017 Jun 19. pii: S1470-2045(17)30439.
    PubMed     Text format    
    
    
    
87. SHAW AT, Kim TM, Crino L, Gridelli C, et al
    Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Lancet Oncol. 2017 Jun 8. pii: S1470-2045(17)30339.
    PubMed     Text format     Abstract available
    
    
    May 2017
88. SHAVERDIAN N, Lisberg AE, Bornazyan K, Veruttipong D, et al
    Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
    Lancet Oncol. 2017 May 24. pii: S1470-2045(17)30380.
    PubMed     Text format     Abstract available
    
    
    
89. DAS M
    Brigatinib effective in ALK-positive non-small-cell lung cancer.
    Lancet Oncol. 2017 May 11. pii: S1470-2045(17)30342.
    PubMed     Text format    
    
    
    March 2017
90. GULLEY JL, Rajan A, Spigel DR, Iannotti N, et al
    Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Lancet Oncol. 2017 Mar 31. pii: S1470-2045(17)30240.
    PubMed     Text format     Abstract available
    
    
    
91. TAKAHASHI T, Yamanaka T, Seto T, Harada H, et al
    Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30230.
    PubMed     Text format     Abstract available
    
    
    
92. SLOTMAN BJ
    Time to reconsider prophylactic cranial irradiation in extensive-stage small-cell lung cancer?
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30193.
    PubMed     Text format    
    
    
    February 2017
93. SCOTT JG, Berglund A, Schell MJ, Mihaylov I, et al
    A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
    Lancet Oncol. 2017;18:202-211.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: